Recombinant factor VIIa: Difference between revisions
Gerald Chi (talk | contribs) (Created page with "{{Refimprove|date=July 2012}} {{Infobox drug | drug_name = | IUPAC_name = | image = | alt = | caption = <!-- Clinical...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
{{ | {{drugbox | ||
| drug_name = | | drug_name = | ||
| IUPAC_name = | | IUPAC_name = | ||
| Line 41: | Line 40: | ||
| molecular_weight = | | molecular_weight = | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Recombinant factor VIIa''' ('''rFVIIa''') is a form of blood [[factor VII]] that has been manufactured via [[recombinant technology]]. The most commonly used rFVIIa is '''eptacog alfa''' ([[International Nonproprietary Name|INN]], trade names '''NovoSeven''' and '''AryoSeven'''). | '''Recombinant factor VIIa''' ('''rFVIIa''') is a form of blood [[factor VII]] that has been manufactured via [[recombinant technology]]. The most commonly used rFVIIa is '''eptacog alfa''' ([[International Nonproprietary Name|INN]], trade names '''NovoSeven''' and '''AryoSeven'''). | ||
| Line 60: | Line 64: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
== External links == | == External links == | ||
Latest revision as of 22:56, 15 April 2015
| Clinical data | |
|---|---|
| Trade names | NovoSeven, AryoSeven |
| AHFS/Drugs.com | Multum Consumer Information |
| Pregnancy category |
|
| Routes of administration | Intravenous injection |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| ChemSpider | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Recombinant factor VIIa (rFVIIa) is a form of blood factor VII that has been manufactured via recombinant technology. The most commonly used rFVIIa is eptacog alfa (INN, trade names NovoSeven and AryoSeven).
Medical use
rFVIIa is not, as of 2012, supported by the evidence for most cases of major bleeding.[1] There is a significant risk of arterial thrombosis with its use and thus other than in those with factor VII deficiency should only be given in clinical trials.[1] Recombinant human factor VII, while initially looking promising in intracerebral hemorrhage, failed to show benefit following further study and is no longer recommended.[2][3]
In people with hemophilia type A and B who have a deficiency of factors VIII and IX, these two factors are administered for controlling bleeding or as prophylaxis medication before starting surgeries. However, in some cases they subsequently develop neutralizing antibodies (NAb) against the drug. These NAbs increase over time and inhibit the action of (coagulation) in the persons body. rFVIIa, which is activated form factor VII, bypasses factors VIII and IX and causes coagulation of blood without the need for factors VIII and IX. This is important for some patients to shift to proper blood factors according to their level of NAbs. Other indications include use for patients with acquired hemophilia, people born with a deficiency of factor VII, and people with Glanzmann's thrombasthenia.
Another possible use is for partial reversal of new oral anticoagulants such as dabigatran, rivaroxaban, or apixaban.[4]
Mechanism of action
This treatment results in activation of the extrinsic pathway of blood coagulation.
Manufacture
rFVIIa is a glycoprotein which is produced by recombinant DNA technology. AryoSeven is formulated totally similar[clarification needed] to the original drug with the name of NovoSeven. The product is the first biosimilar or biogeneric of the above mentioned drug. This biomedicine is produced in baby hamster kidney cells (BHK) and has similar characteristics and functions with the native blood factor VII.
Route of administration
rFVIIa is normally administered intravenously (IV) under physician supervision.
References
- ↑ 1.0 1.1 Simpson, E; Lin, Y; Stanworth, S; Birchall, J; Doree, C; Hyde, C (Mar 14, 2012). "Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia". Cochrane database of systematic reviews (Online). 3: CD005011. doi:10.1002/14651858.CD005011.pub4. PMID 22419303.
- ↑ Mayer S, Brun N, Begtrup K, Broderick J, Davis S, Diringer M, Skolnick B, Steiner T (2005). "Recombinant activated factor VII for acute intracerebral hemorrhage". N. Engl. J. Med. 352 (8): 777–85. doi:10.1056/NEJMoa042991. PMID 15728810.
- ↑ Mayer SA, Brun NC, Begtrup K; et al. (May 2008). "Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage". N. Engl. J. Med. 358 (20): 2127–37. doi:10.1056/NEJMoa0707534. PMID 18480205.
- ↑ Throm Haemost 2012; 108:625
External links
- Pages with script errors
- CS1 maint: Multiple names: authors list
- CS1 maint: Explicit use of et al.
- Template:drugs.com link with non-standard subpage
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Infobox drug tracked parameters
- Wikipedia articles needing clarification from May 2014
- Articles with invalid date parameter in template
- Glycoproteins